Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan
AbstractBackground Deucravacitinib is a selective oral tyrosine kinase 2 (TYK2) inhibitor recently approved for psoriasis.Objectives We aimed to evaluate the real-world effectiveness and safety of deucravacitinib for psoriasis.Methods We analyzed 33 Japanese patients with psoriasis (23 with plaque p...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |